MannKind Corp. About
MannKind MannKind is a biopharmaceutical company focused on the
discovery, development and commercialization of therapeutic products for diseases
including diabetes, cancer, inflammatory, and autoimmune diseases. MannKind's
lead product, the Technosphere® Insulin System, currently is in late Phase 2 clinical
trials for the treatment of diabetes. This therapy consists of our proprietary
dry powder Technosphere® formulation of insulin that is inhaled into the deep
lung using our MedTone™ inhaler. Clinical indications suggest that our proprietary
Technosphere® Insulin System’s performance characteristics, unique kinetics, convenience
and ease of use may have the potential to change the current diabetes treatment
paradigm. Our Technosphere® research activities are complemented by additional
efforts aimed at the discovery and development of novel drugs. We are developing
additional applications for our proprietary Technosphere® formulation technology
by formulating other drugs for pulmonary delivery, primarily for metabolic and
immunological diseases. We are also developing therapies for the treatment of
solid-tumor cancers. Pulmonary
Delivery of Insulin --Technosphere® Insulin System for diabetes More
on MannKind